These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Outer membrane vesicles of Shigella boydii type 4 induce passive immunity in neonatal mice. Mitra S; Barman S; Nag D; Sinha R; Saha DR; Koley H FEMS Immunol Med Microbiol; 2012 Nov; 66(2):240-50. PubMed ID: 22762732 [TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a. Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120 [TBL] [Abstract][Full Text] [Related]
27. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a. Dharmasena MN; Osorio M; Takeda K; Stibitz S; Kopecko DJ Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046309 [TBL] [Abstract][Full Text] [Related]
28. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538 [TBL] [Abstract][Full Text] [Related]
29. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Rahman KM; Arifeen SE; Zaman K; Rahman M; Raqib R; Yunus M; Begum N; Islam MS; Sohel BM; Rahman M; Venkatesan M; Hale TL; Isenbarger DW; Sansonetti PJ; Black RE; Baqui AH Vaccine; 2011 Feb; 29(6):1347-54. PubMed ID: 21040694 [TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084 [TBL] [Abstract][Full Text] [Related]
31. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. Tacket CO; Losonsky G; Link H; Hoang Y; Guesry P; Hilpert H; Levine MM N Engl J Med; 1988 May; 318(19):1240-3. PubMed ID: 3283555 [TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Kärnell A; Li A; Zhao CR; Karlsson K; Nguyen BM; Lindberg AA Vaccine; 1995 Jan; 13(1):88-99. PubMed ID: 7762285 [TBL] [Abstract][Full Text] [Related]
33. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Oaks EV; Turbyfill KR Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513 [TBL] [Abstract][Full Text] [Related]
34. New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies. Shim DH; Suzuki T; Chang SY; Park SM; Sansonetti PJ; Sasakawa C; Kweon MN J Immunol; 2007 Feb; 178(4):2476-82. PubMed ID: 17277155 [TBL] [Abstract][Full Text] [Related]
35. Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a. Hartman AB; Van de Verg LL; Mainhart CR; Tall BD; Smith-Gill SJ Clin Diagn Lab Immunol; 1996 Sep; 3(5):584-9. PubMed ID: 8877140 [TBL] [Abstract][Full Text] [Related]
36. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice. Farzam N; Ramon-Saraf R; Banet-Levi Y; Lerner-Geva L; Ashkenazi S; Kubler-Kielb J; Vinogradov E; Robbins JB; Schneerson R Vaccine; 2017 Sep; 35(37):4990-4996. PubMed ID: 28797729 [TBL] [Abstract][Full Text] [Related]
37. Novel self-sampling culture method to monitor excretion of live, oral Shigella flexneri 2a vaccine SC602 during a community-based phase 1 trial. Teska JD; Coster T; Byrne WR; Colbert JR; Taylor D; Venkatesan M; Hale TL J Lab Clin Med; 1999 Aug; 134(2):141-6. PubMed ID: 10444027 [TBL] [Abstract][Full Text] [Related]
38. Protection against invasion of the mouse pulmonary epithelium by a monoclonal IgA directed against Shigella flexneri lipopolysaccharide. Phalipon A; Michetti P; Kaufmann M; Cavaillon JM; Huerre M; Kraehenbuhl JP; Sansonetti PJ Ann N Y Acad Sci; 1994 Aug; 730():356-8. PubMed ID: 8080209 [No Abstract] [Full Text] [Related]
39. Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y. Ahmed ZU; Sarker MR; Sack DA Vaccine; 1990 Apr; 8(2):153-8. PubMed ID: 2186582 [TBL] [Abstract][Full Text] [Related]
40. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. Cohen D; Green MS; Block C; Rouach T; Ofek I J Infect Dis; 1988 May; 157(5):1068-71. PubMed ID: 3283258 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]